Actelion Ltd.'s Experimental Drug Clazosentan for Brain Hemorrhage Fails to Meet Study Goal

Reuters -- Shares in Switzerland's Actelion (ATLN.VX) fall more than 7 percent and are the top looser on the Swiss blue-chip index .SSMI following news Actelion's haemorrahage drug clazosentan failed in a late-stage study, lessening the chances of it making it to market.

Back to news